1. Clinical Outcomes of Patients with Squamous Cell Carcinoma of the Bladder Compared with Urothelial Carcinoma with Extensive or Focal Squamous Differentiation after Radical Treatment. Issue 2 (February 2019) Authors: Young, T.; Vaughan, G.; Enting, D.; Hughes, S.; Khan, S.; Thurairaja, R. Journal: Clinical oncology Issue: Volume 31:Issue 2(2019) Page Start: e27 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Outcomes, Safety and Prognostic Factors of Patients Receiving Immune Checkpoint Inhibitors for Urothelial Carcinoma: Analysis of Real World Evidence at Guy's Hospital. Issue 5 (May 2020) Authors: Kieran, R.; Chow, B.; Souahli, A.; Moss, C.; Josephs, D.; Enting, D. Journal: Clinical oncology Issue: Volume 32:Issue 5(2020) Page Start: e133 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Using Real-world Data to Define a Validated Nomogram for Advanced Bladder Cancer Patients Who Respond to Immunotherapy. Issue 10 (October 2022) Authors: Elumalai, T.; Croxford, W.; Buijtenhuijs, B.; Conroy, R.; Sanderson, B.; Enting, D.; Aversa, C.; Doss, G.; Das, A.; Vasudev, N.S.; Kitetere, E.; Tolan, S.; Law, A.; Hoskin, P.; Mistry, H.; Choudhury, A. Journal: Clinical oncology Issue: Volume 34:Issue 10(2022) Page Start: 642 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗